You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBromocriptine
Accession NumberDB01200  (APRD00622)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.
Structure
Thumb
Synonyms
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
2-Bromo-alpha-ergocryptine
2-Bromo-alpha-ergokryptin
2-Bromo-alpha-ergokryptine
2-bromo-α-ergocryptine
2-bromo-α-ergokryptin
2-bromo-α-ergokryptine
Bromocriptina
Bromocriptinum
Bromocryptine
Bromoergocriptine
Bromoergocryptine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bromocriptinetablet2.5 mgoralPharmel Inc1998-09-03Not applicableCanada
Bromocriptinecapsule5 mgoralAa Pharma Inc1997-01-08Not applicableCanada
Bromocriptinecapsule5 mgoralPharmel Inc1998-09-03Not applicableCanada
Bromocriptinetablet2.5 mgoralAa Pharma Inc1994-12-31Not applicableCanada
Bromocriptine-2.5 - Tab 2.5mgtablet2.5 mgoralPro Doc Limitee1996-12-312010-07-13Canada
Bromocriptine-5capsule5 mgoralPro Doc Limitee1998-08-112010-07-13Canada
Co Bromocriptine Capsules 5mgcapsule5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Co Bromocriptine Tablets 2.5mgtablet2.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Cyclosettablet.8 mg/1oralSantarus, Inc.2010-11-15Not applicableUs
Dom-bromocriptinetablet2.5 mgoralDominion Pharmacal1998-10-22Not applicableCanada
Dom-bromocriptinecapsule5 mgoralDominion Pharmacal1998-10-22Not applicableCanada
Nu-bromocriptinetablet2.5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-bromocriptinecapsule5.0 mgoralNu Pharm IncNot applicableNot applicableCanada
Parlodelcapsule, gelatin coated5 mg/1oralValidus Pharmaceuticals LLC2014-04-28Not applicableUs
Parlodeltablet2.5 mg/1oralValidus Pharmaceuticals LLC2014-06-20Not applicableUs
Parlodel Cap 5mgcapsule5 mgoralNovartis Pharmaceuticals Canada Inc1983-12-312005-09-09Canada
Parlodel Tab 2.5mgtablet2.5 mgoralNovartis Pharmaceuticals Canada Inc1976-12-312007-07-18Canada
PMS-bromocriptinetablet2.5 mgoralPharmascience Inc1998-03-09Not applicableCanada
PMS-bromocriptinecapsule5 mgoralPharmascience Inc1998-03-05Not applicableCanada
Syn-bromocriptine Cap 5mgcapsule5 mgoralSyncare Pharmaceutical Inc.1994-12-311997-08-11Canada
Syn-bromocriptine Tab 2.5mgtablet2.5 mgoralSyncare Pharmaceutical Inc.1994-12-311997-08-11Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bromocriptine Mesylatetablet2.5 mg/1oralCarilion Materials Management2008-10-01Not applicableUs
Bromocriptine Mesylatetablet2.5 mg/1oralKAISER FOUNDATION HOSPITALS2014-10-10Not applicableUs
Bromocriptine Mesylatetablet2.5 mg/1oralSandoz Inc1998-01-13Not applicableUs
Bromocriptine Mesylatecapsule5 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-01-23Not applicableUs
Bromocriptine Mesylatetablet2.5 mg/1oralMylan Pharmaceuticals Inc.2013-06-06Not applicableUs
Bromocriptine Mesylatetablet2.5 mg/1oralPhysicians Total Care, Inc.2006-09-08Not applicableUs
Bromocriptine Mesylatecapsule5 mg/1oralAmerican Health Packaging2010-01-132015-12-29Us
Bromocriptine Mesylatecapsule5 mg/1oralMylan Pharmaceuticals Inc.2013-06-17Not applicableUs
Bromocriptine Mesylatecapsule5 mg/1oralCadila Healthcare Limited2009-01-23Not applicableUs
Bromocriptine Mesylatetablet2.5 mg/1oralPaddock Laboratories, LLC2008-10-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Apo-BromocriptineApotex
BagrenSerono (Brazil)
ErgosetNot Available
Parlodel SnaptabsNovartis
PravidelMeda (Germany, Sweden), Novartis (Canada, discontinued)
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bromocriptine mesylate
ThumbNot applicableDBSALT001209
Categories
UNII3A64E3G5ZO
CAS number25614-03-3
WeightAverage: 654.595
Monoisotopic: 653.221282062
Chemical FormulaC32H40BrN5O5
InChI KeyInChIKey=OZVBMTJYIDMWIL-AYFBDAFISA-N
InChI
InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
IUPAC Name
(4R,7R)-10-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
SMILES
[H][C@@]12CCCN1C(=O)[[email protected]](CC(C)C)N1C(=O)[C@](NC(=O)[[email protected]]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as ergopeptines. These are ergoline derivatives that contain a tripeptide structure attached to the basic ergoline ring in the same location as the amide group of the lysergic acid derivatives.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassErgoline and derivatives
Sub ClassLysergic acids and derivatives
Direct ParentErgopeptines
Alternative Parents
Substituents
  • Hybrid peptide
  • Ergopeptine
  • Lysergic acid amide
  • Indoloquinoline
  • Benzoquinoline
  • Quinoline-3-carboxamide
  • Pyrroloquinoline
  • N-acyl-alpha amino acid or derivatives
  • Quinoline
  • Isoindole or derivatives
  • Indole or derivatives
  • Indole
  • Aralkylamine
  • N-alkylpiperazine
  • Tetrahydropyridine
  • Benzenoid
  • Substituted pyrrole
  • Piperazine
  • Oxazolidinone
  • 1,4-diazinane
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Orthocarboxylic acid derivative
  • Lactam
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Alkanolamine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.
PharmacodynamicsBromocriptine stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D1 and D5 subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D2, D3 and D4 subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D2 and D3 receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D2-receptors. It also exhibits agonist activity (in order of decreasing binding affinity) on 5-hydroxytryptamine (5-HT)1D, dopamine D3, 5-HT1A, 5-HT2A, 5-HT1B, and 5-HT2C receptors, antagonist activity on α2A-adrenergic, α2C, α2B, and dopamine D1 receptors, partial agonist activity at receptor 5-HT2B, and inactivates dopamine D4 and 5-HT7 receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT2A agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion making bromocriptine an effective agent for treating disorders associated with hypersecretion of prolactin. Pulmonary fibrosis may be associated bromocriptine’s agonist activity at 5-HT1B and 5-HT2B receptors.
Mechanism of actionThe dopamine D2 receptor is a 7-transmembrane G-protein coupled receptor associated with Gi proteins. In lactotrophs, stimulation of dopamine D2 receptor causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca2+ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D2 receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders.
Related Articles
AbsorptionApproximately 28% of the oral dose is absorbed; however due to a substantial first pass effect, only 6% of the oral dose reaches the systemic circulation unchanged. Bromocriptine and its metabolites appear in the blood as early as 10 minutes following oral administration and peak plasma concentration are reached within 1-1.5 hours. Serum prolactin may be decreased within 2 hours or oral administration with a maximal effect achieved after 8 hours. Growth hormone concentrations in patients with acromegaly is reduced within 1-2 hours with a single oral dose of 2.5 mg and decreased growth hormone concentrations persist for at least 4-5 hours.
Volume of distributionNot Available
Protein binding90-96% bound to serum albumin
Metabolism

Completely metabolized by the liver, primarily by hydrolysis of the amide bond to produce lysergic acid and a peptide fragment, both inactive and non-toxic. Bromocriptine is metabolized by cytochrome P450 3A4 and excreted primarily in the feces via biliary secretion.

Route of eliminationParent drug and metabolites are almost completely excreted via the liver, and only 6% eliminated via the kidney.
Half life2-8 hours
ClearanceNot Available
ToxicitySymptoms of overdosage include nausea, vomiting, and severe hypotension. The most common adverse effects include nausea, headache, vertigo, constipation, light-headedness, abdominal cramps, nasal congestion, diarrhea, and hypotension.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.915
Blood Brain Barrier-0.9845
Caco-2 permeable-0.6618
P-glycoprotein substrateSubstrate0.8881
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterNon-inhibitor0.837
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7454
CYP450 1A2 substrateNon-inhibitor0.9031
CYP450 2C9 inhibitorInhibitor0.8326
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5149
Ames testNon AMES toxic0.7879
CarcinogenicityNon-carcinogens0.9353
BiodegradationNot ready biodegradable0.9973
Rat acute toxicity2.7499 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9313
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral5 mg
Tabletoral2.5 mg
Capsuleoral5 mg/1
Tabletoral2.5 mg/1
Tabletoral.8 mg/1
Capsuleoral5.0 mg
Capsule, gelatin coatedoral5 mg/1
Prices
Unit descriptionCostUnit
Bromocriptine mesylate powd384.03USD g
Parlodel 5 mg capsule9.25USD capsule
Parlodel 2.5 mg tablet5.64USD tablet
Bromocriptine Mesylate 5 mg capsule5.21USD capsule
Bromocriptine Mesylate 2.5 mg tablet2.28USD tablet
Bromocriptine 2.5 mg tablet2.18USD tablet
Apo-Bromocriptine 5 mg Capsule1.02USD capsule
Pms-Bromocriptine 5 mg Capsule1.02USD capsule
Apo-Bromocriptine 2.5 mg Tablet0.57USD tablet
Pms-Bromocriptine 2.5 mg Tablet0.57USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5468755 No1992-11-212012-11-21Us
US5716957 No1995-02-102015-02-10Us
US7888310 No2003-07-252023-07-25Us
US8137992 No2003-07-252023-07-25Us
US8137993 No2003-07-252023-07-25Us
US8137994 No2003-07-252023-07-25Us
US8431155 No2012-04-302032-04-30Us
US8613947 No2012-04-302032-04-30Us
US8877708 No2010-06-072030-06-07Us
US9192576 No2012-04-302032-04-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point215-218Fluckiger, E.,Troxler, F. and Hofmann, A,; US. Patent 3,752,814; August 14, 1973; assigned to Sandoz Ltd., Switzerland. Fluckiger, E., Troxler, F. and Hofmann, A.; U.S. Patent 3,752,888; August 14, 1973; assigned to Sandoz Ltd., Switzerland.
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0858 mg/mLALOGPS
logP3.2ALOGPS
logP3.89ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)9.68ChemAxon
pKa (Strongest Basic)6.71ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity165.51 m3·mol-1ChemAxon
Polarizability66.44 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Luigi Moro, Achille Fiori, Alberto Natali, “Processes for the preparation of pharmaceutical compositions containing bromocriptine having high stability and related products.” U.S. Patent US5066495, issued May, 1988.

US5066495
General References
  1. Banihashemi B, Albert PR: Dopamine-D2S receptor inhibition of calcium influx, adenylyl cyclase, and mitogen-activated protein kinase in pituitary cells: distinct Galpha and Gbetagamma requirements. Mol Endocrinol. 2002 Oct;16(10):2393-404. [PubMed:12351703 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
  4. Malgaroli A, Vallar L, Elahi FR, Pozzan T, Spada A, Meldolesi J: Dopamine inhibits cytosolic Ca2+ increases in rat lactotroph cells. Evidence of a dual mechanism of action. J Biol Chem. 1987 Oct 15;262(29):13920-7. [PubMed:2443499 ]
  5. Nishina Y, Takano K, Yasufuku-Takano J, Teramoto A, Fujita T: Mechanism of D(2) agonist-induced inhibition of GH secretion from human GH-secreting adenoma cells. Endocr J. 2005 Dec;52(6):775-9. [PubMed:16410672 ]
  6. Vallar L, Meldolesi J: Mechanisms of signal transduction at the dopamine D2 receptor. Trends Pharmacol Sci. 1989 Feb;10(2):74-7. [PubMed:2655242 ]
  7. Vallar L, Vicentini LM, Meldolesi J: Inhibition of inositol phosphate production is a late, Ca2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem. 1988 Jul 25;263(21):10127-34. [PubMed:2839476 ]
External Links
ATC CodesG02CB01N04BC01
AHFS Codes
  • 28:36.20.04
PDB EntriesNot Available
FDA labelDownload (105 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Bromocriptine can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Bromocriptine can be increased when it is combined with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Bromocriptine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe metabolism of Bromocriptine can be decreased when combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AcebutololAcebutolol may increase the vasoconstricting activities of Bromocriptine.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Bromocriptine.
AcepromazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Bromocriptine can be increased when it is combined with Acetaminophen.
AcetophenazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acetophenazine.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Bromocriptine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Bromocriptine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Bromocriptine.
AlbendazoleThe serum concentration of Bromocriptine can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Bromocriptine can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Bromocriptine.
AlectinibThe serum concentration of Bromocriptine can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Bromocriptine can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Bromocriptine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Bromocriptine.
AlmotriptanBromocriptine may increase the vasoconstricting activities of Almotriptan.
AlogliptinThe serum concentration of Bromocriptine can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Bromocriptine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlprenololAlprenolol may increase the vasoconstricting activities of Bromocriptine.
AlprenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
AmantadineThe serum concentration of Bromocriptine can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Bromocriptine.
AmineptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Amineptine.
Aminohippuric acidThe serum concentration of Bromocriptine can be increased when it is combined with Aminohippuric acid.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Bromocriptine.
AmiodaroneThe serum concentration of Bromocriptine can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amisulpride.
AmitriptylineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Amitriptyline.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Bromocriptine.
AmlodipineThe serum concentration of Bromocriptine can be increased when it is combined with Amlodipine.
AmoxapineAmoxapine may increase the hypoglycemic activities of Bromocriptine.
AmoxapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amperozide.
AmprenavirThe serum concentration of Bromocriptine can be increased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Bromocriptine can be increased when it is combined with Amsacrine.
Antithrombin III humanThe serum concentration of Bromocriptine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Bromocriptine can be increased when it is combined with Apixaban.
ApomorphineBromocriptine may increase the vasoconstricting activities of Apomorphine.
AprepitantThe serum concentration of Bromocriptine can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Bromocriptine can be increased when it is combined with Aprotinin.
ArgatrobanThe serum concentration of Bromocriptine can be increased when it is combined with Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aripiprazole.
ArotinololArotinolol may increase the vasoconstricting activities of Bromocriptine.
ArotinololBromocriptine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Bromocriptine.
AsenapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Asenapine.
AstemizoleThe serum concentration of Bromocriptine can be increased when it is combined with Astemizole.
AsunaprevirThe serum concentration of Bromocriptine can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Bromocriptine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Bromocriptine can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Bromocriptine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Bromocriptine can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Bromocriptine.
AzaperoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Azaperone.
AzelastineThe serum concentration of Bromocriptine can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Bromocriptine can be increased when it is combined with Azithromycin.
BatimastatThe serum concentration of Bromocriptine can be increased when it is combined with Batimastat.
BefunololBefunolol may increase the vasoconstricting activities of Bromocriptine.
BefunololBromocriptine may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilThe serum concentration of Bromocriptine can be increased when it is combined with Benazepril.
BenmoxinThe metabolism of Bromocriptine can be decreased when combined with Benmoxin.
BenzamidineThe serum concentration of Bromocriptine can be increased when it is combined with Benzamidine.
BenzocaineThe serum concentration of Bromocriptine can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Bromocriptine can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Bromocriptine.
BetaxololBetaxolol may increase the vasoconstricting activities of Bromocriptine.
BetaxololBromocriptine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
BevantololBevantolol may increase the vasoconstricting activities of Bromocriptine.
BevantololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BexaroteneThe serum concentration of Bromocriptine can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bifeprunox.
BiperidenThe serum concentration of Bromocriptine can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the vasoconstricting activities of Bromocriptine.
BisoprololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
BivalirudinThe serum concentration of Bromocriptine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Bromocriptine can be increased when it is combined with Boceprevir.
BopindololBopindolol may increase the vasoconstricting activities of Bromocriptine.
BopindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BortezomibThe metabolism of Bromocriptine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Bromocriptine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Bromocriptine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bromocriptine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Brexpiprazole.
BufuralolBufuralol may increase the vasoconstricting activities of Bromocriptine.
BufuralolBromocriptine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BupranololBupranolol may increase the vasoconstricting activities of Bromocriptine.
BupranololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BuprenorphineThe serum concentration of Bromocriptine can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Bromocriptine can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Buspirone.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Bromocriptine.
CabergolineCabergoline may increase the vasoconstricting activities of Bromocriptine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Bromocriptine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Bromocriptine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Bromocriptine.
CandesartanThe serum concentration of Bromocriptine can be increased when it is combined with Candesartan.
CandoxatrilThe serum concentration of Bromocriptine can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Bromocriptine can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Bromocriptine can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Bromocriptine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Bromocriptine.
CariprazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cariprazine.
CaroxazoneThe metabolism of Bromocriptine can be decreased when combined with Caroxazone.
CarteololCarteolol may increase the vasoconstricting activities of Bromocriptine.
CarteololBromocriptine may increase the atrioventricular blocking (AV block) activities of Carteolol.
CarvedilolBromocriptine may increase the atrioventricular blocking (AV block) activities of Carvedilol.
CarvedilolThe serum concentration of Bromocriptine can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Bromocriptine can be increased when it is combined with Caspofungin.
CeliprololCeliprolol may increase the vasoconstricting activities of Bromocriptine.
CeliprololBromocriptine may increase the atrioventricular blocking (AV block) activities of Celiprolol.
CeritinibThe serum concentration of Bromocriptine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Bromocriptine.
ChloroquineThe serum concentration of Bromocriptine can be increased when it is combined with Chloroquine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorpromazine.
ChlorpromazineThe serum concentration of Bromocriptine can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Bromocriptine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorprothixene.
ChlorprothixeneThe serum concentration of Bromocriptine can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Bromocriptine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Bromocriptine can be decreased when it is combined with Cholic Acid.
ChymostatinThe serum concentration of Bromocriptine can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Bromocriptine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Bromocriptine can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Bromocriptine can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Bromocriptine.
CiprofloxacinThe serum concentration of Bromocriptine can be increased when it is combined with Ciprofloxacin.
CirazolineBromocriptine may increase the hypertensive activities of Cirazoline.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Bromocriptine.
CitalopramCitalopram may increase the hypoglycemic activities of Bromocriptine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Bromocriptine.
ClarithromycinThe serum concentration of Bromocriptine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Bromocriptine can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Bromocriptine.
ClofazimineThe serum concentration of Bromocriptine can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Bromocriptine.
ClomipramineClomipramine may increase the hypoglycemic activities of Bromocriptine.
ClomipramineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Bromocriptine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Bromocriptine.
ClotrimazoleThe metabolism of Bromocriptine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clozapine.
CobicistatThe serum concentration of Bromocriptine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Bromocriptine.
ColchicineThe serum concentration of Bromocriptine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Bromocriptine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Bromocriptine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Bromocriptine.
CrizotinibThe metabolism of Bromocriptine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Bromocriptine.
CyamemazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cyamemazine.
CyclobenzaprineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Cyclobenzaprine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cyclobenzaprine.
CyclophosphamideThe serum concentration of Bromocriptine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.
CyclosporineThe metabolism of Bromocriptine can be decreased when combined with Cyclosporine.
Dabigatran etexilateThe serum concentration of Bromocriptine can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Bromocriptine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Bromocriptine.
DaclatasvirThe serum concentration of Bromocriptine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Bromocriptine can be increased when it is combined with Dactinomycin.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Bromocriptine.
DapiprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Bromocriptine.
DarunavirThe serum concentration of Bromocriptine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Bromocriptine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Bromocriptine can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Bromocriptine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Bromocriptine.
DeferasiroxThe serum concentration of Bromocriptine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Bromocriptine can be decreased when combined with Delavirdine.
DesipramineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desipramine.
DesloratadineThe serum concentration of Bromocriptine can be increased when it is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desvenlafaxine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Bromocriptine.
DexamethasoneThe serum concentration of Bromocriptine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Bromocriptine.
DextromethorphanThe serum concentration of Bromocriptine can be increased when it is combined with Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Bromocriptine.
DiclofenacThe serum concentration of Bromocriptine can be increased when it is combined with Diclofenac.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bromocriptine.
DiflunisalDiflunisal may increase the hypoglycemic activities of Bromocriptine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Bromocriptine.
DigoxinThe serum concentration of Bromocriptine can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Bromocriptine.
DihydroergotamineDihydroergotamine may increase the vasoconstricting activities of Bromocriptine.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Bromocriptine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Bromocriptine.
DiltiazemThe metabolism of Bromocriptine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Bromocriptine.
DipyridamoleThe serum concentration of Bromocriptine can be increased when it is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Bromocriptine.
DolasetronDolasetron may increase the serotonergic activities of Bromocriptine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Bromocriptine.
DosulepinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Dosulepin.
DoxazosinThe serum concentration of Bromocriptine can be increased when it is combined with Doxazosin.
DoxepinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Doxepin.
DoxorubicinThe serum concentration of Bromocriptine can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bromocriptine.
DoxycyclineThe metabolism of Bromocriptine can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Bromocriptine can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Bromocriptine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Droperidol.
DroxidopaBromocriptine may increase the hypertensive activities of Droxidopa.
DuloxetineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Duloxetine.
DuloxetineDuloxetine may decrease the antihypertensive activities of Bromocriptine.
EcabetThe serum concentration of Bromocriptine can be increased when it is combined with Ecabet.
EdoxabanThe serum concentration of Bromocriptine can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Bromocriptine can be decreased when it is combined with Efavirenz.
ElafinThe serum concentration of Bromocriptine can be increased when it is combined with Elafin.
ElbasvirThe serum concentration of Bromocriptine can be increased when it is combined with Elbasvir.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Bromocriptine.
EletriptanBromocriptine may increase the vasoconstricting activities of Eletriptan.
EnalaprilThe serum concentration of Bromocriptine can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Bromocriptine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Bromocriptine can be increased when it is combined with Enalkiren.
EnzalutamideThe serum concentration of Bromocriptine can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Bromocriptine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ergoloid mesylate.
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Bromocriptine.
ErgonovineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ergonovine.
ErgonovineErgonovine may increase the vasoconstricting activities of Bromocriptine.
ErgotamineBromocriptine may increase the hypertensive activities of Ergotamine.
ErgotamineErgotamine may increase the vasoconstricting activities of Bromocriptine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Bromocriptine.
ErythromycinThe metabolism of Bromocriptine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Bromocriptine.
EscitalopramEscitalopram may increase the hypoglycemic activities of Bromocriptine.
EscitalopramThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Bromocriptine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Esmirtazapine.
EsmololEsmolol may increase the vasoconstricting activities of Bromocriptine.
EsmololBromocriptine may increase the atrioventricular blocking (AV block) activities of Esmolol.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Bromocriptine.
EstramustineThe serum concentration of Bromocriptine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Bromocriptine can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Bromocriptine.
EstroneThe serum concentration of Bromocriptine can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Bromocriptine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Bromocriptine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bromocriptine.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Bromocriptine.
EtoposideThe serum concentration of Bromocriptine can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Bromocriptine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bromocriptine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Bromocriptine.
FelodipineThe serum concentration of Bromocriptine can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fencamfamine.
FenfluramineFenfluramine may increase the hypoglycemic activities of Bromocriptine.
FentanylThe serum concentration of Bromocriptine can be increased when it is combined with Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Bromocriptine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Bromocriptine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Bromocriptine.
FluconazoleThe metabolism of Bromocriptine can be decreased when combined with Fluconazole.
FluoxetineFluoxetine may increase the hypoglycemic activities of Bromocriptine.
FluoxetineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluoxetine.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Bromocriptine.
FlupentixolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Flupentixol.
FlupentixolThe serum concentration of Bromocriptine can be increased when it is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluphenazine.
FluphenazineThe serum concentration of Bromocriptine can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Bromocriptine can be increased when it is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Bromocriptine.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Bromocriptine.
FluvoxamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Bromocriptine can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Bromocriptine can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Bromocriptine can be increased when it is combined with Fosinopril.
FosphenytoinThe metabolism of Bromocriptine can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Bromocriptine.
FrovatriptanBromocriptine may increase the vasoconstricting activities of Frovatriptan.
FurazolidoneThe metabolism of Bromocriptine can be decreased when combined with Furazolidone.
Fusidic AcidThe serum concentration of Bromocriptine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Bromocriptine.
GeldanamycinThe serum concentration of Bromocriptine can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Bromocriptine.
GenisteinThe serum concentration of Bromocriptine can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Bromocriptine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Bromocriptine can be increased when it is combined with Glycerol.
GM6001The serum concentration of Bromocriptine can be increased when it is combined with GM6001.
Gramicidin DThe serum concentration of Bromocriptine can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the serotonergic activities of Bromocriptine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Bromocriptine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Bromocriptine.
HaloperidolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Haloperidol.
HaloperidolThe serum concentration of Bromocriptine can be increased when it is combined with Haloperidol.
HirulogThe serum concentration of Bromocriptine can be increased when it is combined with Hirulog.
HydracarbazineThe metabolism of Bromocriptine can be decreased when combined with Hydracarbazine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Bromocriptine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Bromocriptine.
IdelalisibThe serum concentration of Bromocriptine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Iloperidone.
ImatinibThe metabolism of Bromocriptine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Bromocriptine.
ImipramineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Imipramine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Bromocriptine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Bromocriptine.
IndalpineIndalpine may increase the hypoglycemic activities of Bromocriptine.
IndenololIndenolol may increase the vasoconstricting activities of Bromocriptine.
IndenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Indenolol.
IndinavirThe serum concentration of Bromocriptine can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Bromocriptine can be increased when it is combined with Indomethacin.
IproclozideThe metabolism of Bromocriptine can be decreased when combined with Iproclozide.
IproniazidThe metabolism of Bromocriptine can be decreased when combined with Iproniazid.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Bromocriptine.
IsavuconazoniumThe metabolism of Bromocriptine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isocarboxazid.
IsocarboxazidThe metabolism of Bromocriptine can be decreased when combined with Isocarboxazid.
IsoflurophateThe serum concentration of Bromocriptine can be increased when it is combined with Isoflurophate.
IsradipineThe metabolism of Bromocriptine can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Bromocriptine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Bromocriptine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Bromocriptine.
IxazomibThe serum concentration of Bromocriptine can be increased when it is combined with Ixazomib.
KetamineThe serum concentration of Bromocriptine can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Bromocriptine.
KetoconazoleThe serum concentration of Bromocriptine can be increased when it is combined with Ketoconazole.
LabetalolLabetalol may increase the vasoconstricting activities of Bromocriptine.
LabetalolBromocriptine may increase the atrioventricular blocking (AV block) activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Bromocriptine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Bromocriptine.
LanreotideThe serum concentration of Bromocriptine can be increased when it is combined with Lanreotide.
LansoprazoleThe serum concentration of Bromocriptine can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Bromocriptine can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Bromocriptine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Bromocriptine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Bromocriptine.
LepirudinThe serum concentration of Bromocriptine can be increased when it is combined with Lepirudin.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Bromocriptine.
LevobunololLevobunolol may increase the vasoconstricting activities of Bromocriptine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Bromocriptine.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Bromocriptine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Bromocriptine.
LevothyroxineThe serum concentration of Bromocriptine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Bromocriptine can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Linagliptin.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Bromocriptine.
LiothyronineThe serum concentration of Bromocriptine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Bromocriptine can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Bromocriptine can be increased when it is combined with Lisinopril.
LisurideBromocriptine may increase the vasoconstricting activities of Lisuride.
LithiumThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lithium.
LomitapideThe serum concentration of Bromocriptine can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Bromocriptine.
LopinavirThe serum concentration of Bromocriptine can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Bromocriptine can be increased when it is combined with Loratadine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Bromocriptine.
LosartanThe serum concentration of Bromocriptine can be increased when it is combined with Losartan.
LovastatinThe metabolism of Bromocriptine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Loxapine.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Bromocriptine.
Lu AA21004Bromocriptine may increase the vasoconstricting activities of Lu AA21004.
LuliconazoleThe serum concentration of Bromocriptine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Bromocriptine can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lurasidone.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Bromocriptine.
MaprotilineThe serum concentration of Bromocriptine can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Maprotiline.
MebanazineThe metabolism of Bromocriptine can be decreased when combined with Mebanazine.
MebendazoleThe serum concentration of Bromocriptine can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Bromocriptine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Bromocriptine can be increased when it is combined with Megestrol acetate.
MelperoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Melperone.
MephentermineBromocriptine may increase the hypertensive activities of Mephentermine.
MeprobamateThe serum concentration of Bromocriptine can be increased when it is combined with Meprobamate.
MesalazineMesalazine may increase the hypoglycemic activities of Bromocriptine.
MesoridazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mesoridazine.
MetaraminolBromocriptine may increase the hypertensive activities of Metaraminol.
MethadoneThe serum concentration of Bromocriptine can be increased when it is combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bromocriptine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methotrimeprazine.
MethoxamineBromocriptine may increase the hypertensive activities of Methoxamine.
Methylene blueThe metabolism of Bromocriptine can be decreased when combined with Methylene blue.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Bromocriptine.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Bromocriptine.
MetipranololMetipranolol may increase the vasoconstricting activities of Bromocriptine.
MetoclopramideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metoclopramide.
MetoprololThe serum concentration of Bromocriptine can be increased when it is combined with Metoprolol.
MianserinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mianserin.
MibefradilThe serum concentration of Bromocriptine can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Bromocriptine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Bromocriptine can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Bromocriptine.
MidodrineBromocriptine may increase the hypertensive activities of Midodrine.
MifepristoneThe metabolism of Bromocriptine can be decreased when combined with Mifepristone.
MilnacipranMilnacipran may increase the hypoglycemic activities of Bromocriptine.
MilnacipranThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Milnacipran.
MinaprineThe metabolism of Bromocriptine can be decreased when combined with Minaprine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Bromocriptine.
MirtazapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mirtazapine.
MitomycinThe serum concentration of Bromocriptine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Bromocriptine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Bromocriptine can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Bromocriptine.
MoclobemideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Moclobemide.
MoclobemideThe metabolism of Bromocriptine can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Bromocriptine can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Bromocriptine can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Bromocriptine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bromocriptine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Bromocriptine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NadololNadolol may increase the vasoconstricting activities of Bromocriptine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Bromocriptine.
NafcillinThe serum concentration of Bromocriptine can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bromocriptine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Bromocriptine.
NaltrexoneThe serum concentration of Bromocriptine can be increased when it is combined with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Bromocriptine.
NaratriptanBromocriptine may increase the vasoconstricting activities of Naratriptan.
NaringeninThe serum concentration of Bromocriptine can be increased when it is combined with Naringenin.
NCX 4016The serum concentration of Bromocriptine can be increased when it is combined with NCX 4016.
NefazodoneThe serum concentration of Bromocriptine can be decreased when it is combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nefazodone.
NelfinavirThe serum concentration of Bromocriptine can be increased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Bromocriptine can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Bromocriptine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Bromocriptine can be decreased when combined with Nevirapine.
NialamideThe metabolism of Bromocriptine can be decreased when combined with Nialamide.
NicardipineThe serum concentration of Bromocriptine can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Bromocriptine can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Bromocriptine.
NilotinibThe metabolism of Bromocriptine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Bromocriptine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Bromocriptine.
NisoldipineThe serum concentration of Bromocriptine can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Bromocriptine can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Bromocriptine can be increased when it is combined with Nitrendipine.
NitroglycerinBromocriptine may decrease the vasodilatory activities of Nitroglycerin.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Bromocriptine.
NorethisteroneThe serum concentration of Bromocriptine can be decreased when it is combined with Norethisterone.
NortriptylineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nortriptyline.
OctamoxinThe metabolism of Bromocriptine can be decreased when combined with Octamoxin.
OctreotideThe serum concentration of Bromocriptine can be increased when it is combined with Octreotide.
OlanzapineOlanzapine may increase the hypoglycemic activities of Bromocriptine.
OlanzapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Olanzapine.
OlaparibThe metabolism of Bromocriptine can be decreased when combined with Olaparib.
OmapatrilatThe serum concentration of Bromocriptine can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Bromocriptine.
OmeprazoleThe serum concentration of Bromocriptine can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Bromocriptine.
OsanetantThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Osanetant.
OsimertinibThe serum concentration of Bromocriptine can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Bromocriptine can be increased when it is combined with Otamixaban.
OxandroloneOxandrolone may increase the hypoglycemic activities of Bromocriptine.
OxprenololOxprenolol may increase the vasoconstricting activities of Bromocriptine.
OxprenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Bromocriptine.
P-NitrophenolThe serum concentration of Bromocriptine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Bromocriptine can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Bromocriptine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Paliperidone.
Palmitic AcidThe serum concentration of Bromocriptine can be increased when it is combined with Palmitic Acid.
PalonosetronPalonosetron may increase the serotonergic activities of Bromocriptine.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Bromocriptine.
PantoprazoleThe serum concentration of Bromocriptine can be increased when it is combined with Pantoprazole.
PargylineThe metabolism of Bromocriptine can be decreased when combined with Pargyline.
ParoxetineParoxetine may increase the hypoglycemic activities of Bromocriptine.
ParoxetineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Paroxetine.
PasireotideThe serum concentration of Bromocriptine can be increased when it is combined with Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Bromocriptine.
PegvisomantPegvisomant may increase the hypoglycemic activities of Bromocriptine.
PenbutololPenbutolol may increase the vasoconstricting activities of Bromocriptine.
PenbutololBromocriptine may increase the atrioventricular blocking (AV block) activities of Penbutolol.
PentobarbitalThe metabolism of Bromocriptine can be increased when combined with Pentobarbital.
PergolideBromocriptine may increase the vasoconstricting activities of Pergolide.
PerindoprilThe serum concentration of Bromocriptine can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromocriptine.
PhenelzineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Phenelzine.
PhenelzineThe metabolism of Bromocriptine can be decreased when combined with Phenelzine.
PheniprazineThe metabolism of Bromocriptine can be decreased when combined with Pheniprazine.
PhenobarbitalThe serum concentration of Bromocriptine can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Bromocriptine.
PhenoxypropazineThe metabolism of Bromocriptine can be decreased when combined with Phenoxypropazine.
PhenylephrineBromocriptine may increase the hypertensive activities of Phenylephrine.
PhenytoinThe metabolism of Bromocriptine can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Bromocriptine.
PhosphoramidonThe serum concentration of Bromocriptine can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pimozide.
PimozideThe serum concentration of Bromocriptine can be increased when it is combined with Pimozide.
PindololPindolol may increase the vasoconstricting activities of Bromocriptine.
PindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipotiazine.
PirlindoleThe metabolism of Bromocriptine can be decreased when combined with Pirlindole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Bromocriptine.
PivhydrazineThe metabolism of Bromocriptine can be decreased when combined with Pivhydrazine.
Platelet Activating FactorThe serum concentration of Bromocriptine can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Bromocriptine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Bromocriptine.
PosaconazoleThe serum concentration of Bromocriptine can be increased when it is combined with Posaconazole.
PractololPractolol may increase the vasoconstricting activities of Bromocriptine.
PractololBromocriptine may increase the atrioventricular blocking (AV block) activities of Practolol.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Bromocriptine.
PrazosinThe serum concentration of Bromocriptine can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Bromocriptine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Bromocriptine.
PrimidoneThe metabolism of Bromocriptine can be increased when combined with Primidone.
PrinomastatThe serum concentration of Bromocriptine can be increased when it is combined with Prinomastat.
ProbenecidThe serum concentration of Bromocriptine can be increased when it is combined with Probenecid.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Bromocriptine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Bromocriptine can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Bromocriptine.
PromazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Promazine.
PromethazineThe serum concentration of Bromocriptine can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Promethazine.
PropafenoneThe serum concentration of Bromocriptine can be increased when it is combined with Propafenone.
PropericiazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Propericiazine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Bromocriptine.
ProtriptylineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Bromocriptine.
PRX-00023Bromocriptine may increase the vasoconstricting activities of PRX-00023.
QuercetinThe serum concentration of Bromocriptine can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Quetiapine.
QuinacrineThe serum concentration of Bromocriptine can be increased when it is combined with Quinacrine.
QuinaprilThe serum concentration of Bromocriptine can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Bromocriptine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Bromocriptine can be increased when it is combined with Quinine.
RamiprilThe serum concentration of Bromocriptine can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Bromocriptine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Bromocriptine.
RasagilineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rasagiline.
RasagilineThe metabolism of Bromocriptine can be decreased when combined with Rasagiline.
ReboxetineThe serum concentration of Bromocriptine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Bromocriptine can be increased when it is combined with Regorafenib.
RemikirenThe serum concentration of Bromocriptine can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Reserpine.
ReserpineThe serum concentration of Bromocriptine can be decreased when it is combined with Reserpine.
RifabutinThe metabolism of Bromocriptine can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Bromocriptine can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Bromocriptine.
RifapentineThe metabolism of Bromocriptine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Bromocriptine.
RilpivirineThe serum concentration of Bromocriptine can be increased when it is combined with Rilpivirine.
RisperidoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Risperidone.
RitonavirThe serum concentration of Bromocriptine can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Bromocriptine can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Bromocriptine.
RizatriptanBromocriptine may increase the vasoconstricting activities of Rizatriptan.
RolapitantThe serum concentration of Bromocriptine can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Bromocriptine.
RopiniroleBromocriptine may increase the vasoconstricting activities of Ropinirole.
SafrazineThe metabolism of Bromocriptine can be decreased when combined with Safrazine.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Bromocriptine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Bromocriptine.
SaquinavirThe serum concentration of Bromocriptine can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Saxagliptin.
ScopolamineThe serum concentration of Bromocriptine can be increased when it is combined with Scopolamine.
SelegilineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Selegiline.
SelegilineThe metabolism of Bromocriptine can be decreased when combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Bromocriptine.
SertindoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sertindole.
SertralineSertraline may increase the hypoglycemic activities of Bromocriptine.
SertralineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sertraline.
SildenafilThe metabolism of Bromocriptine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Bromocriptine.
SiltuximabThe serum concentration of Bromocriptine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Bromocriptine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Bromocriptine can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Bromocriptine can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Sitagliptin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Bromocriptine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Bromocriptine.
SotalolSotalol may increase the vasoconstricting activities of Bromocriptine.
SotalolBromocriptine may increase the atrioventricular blocking (AV block) activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Bromocriptine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Bromocriptine.
SpiraprilThe serum concentration of Bromocriptine can be increased when it is combined with Spirapril.
SpironolactoneThe serum concentration of Bromocriptine can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Bromocriptine can be decreased when it is combined with St. John's Wort.
StanozololStanozolol may increase the hypoglycemic activities of Bromocriptine.
StaurosporineThe serum concentration of Bromocriptine can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Bromocriptine can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Bromocriptine can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Bromocriptine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Bromocriptine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulpiride.
SumatriptanThe serum concentration of Bromocriptine can be increased when it is combined with Sumatriptan.
SumatriptanBromocriptine may increase the vasoconstricting activities of Sumatriptan.
SunitinibThe serum concentration of Bromocriptine can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Bromocriptine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Bromocriptine can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Bromocriptine.
TamoxifenThe serum concentration of Bromocriptine can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Bromocriptine.
TapentadolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tapentadol.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Bromocriptine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Bromocriptine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Bromocriptine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Bromocriptine can be increased when it is combined with Telaprevir.
TelithromycinThe metabolism of Bromocriptine can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Bromocriptine can be increased when it is combined with Telmisartan.
TemocaprilThe serum concentration of Bromocriptine can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Bromocriptine.
TerazosinThe serum concentration of Bromocriptine can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Bromocriptine can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Bromocriptine can be decreased when it is combined with Tesmilifene.
TestosteroneTestosterone may increase the hypoglycemic activities of Bromocriptine.
ThioproperazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thioridazine.
ThiorphanThe serum concentration of Bromocriptine can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thiothixene.
TianeptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Tianeptine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Bromocriptine.
TiclopidineThe metabolism of Bromocriptine can be decreased when combined with Ticlopidine.
TimololTimolol may increase the vasoconstricting activities of Bromocriptine.
TimololThe serum concentration of Timolol can be increased when it is combined with Bromocriptine.
TipranavirThe serum concentration of Bromocriptine can be increased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Bromocriptine can be decreased when it is combined with Tocilizumab.
ToloxatoneThe metabolism of Bromocriptine can be decreased when combined with Toloxatone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Bromocriptine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Bromocriptine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Bromocriptine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromocriptine.
TrandolaprilThe serum concentration of Bromocriptine can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineThe metabolism of Bromocriptine can be decreased when combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tranylcypromine.
TranylcypromineThe metabolism of Bromocriptine can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Bromocriptine.
TrazodoneTrazodone may increase the hypoglycemic activities of Bromocriptine.
TrazodoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Trazodone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Trifluoperazine.
TrifluoperazineThe serum concentration of Bromocriptine can be increased when it is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Triflupromazine.
TriflupromazineThe serum concentration of Bromocriptine can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Bromocriptine can be decreased when it is combined with Trimethoprim.
TrimipramineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Trimipramine.
TroleandomycinThe serum concentration of Bromocriptine can be increased when it is combined with Troleandomycin.
UbenimexThe serum concentration of Bromocriptine can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Bromocriptine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Bromocriptine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Bromocriptine.
VenlafaxineThe metabolism of Bromocriptine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Bromocriptine.
VerapamilThe metabolism of Bromocriptine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Bromocriptine.
VilazodoneVilazodone may increase the hypoglycemic activities of Bromocriptine.
VilazodoneBromocriptine may increase the vasoconstricting activities of Vilazodone.
VildagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Bromocriptine can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Bromocriptine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Bromocriptine.
VincristineThe serum concentration of Bromocriptine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Bromocriptine can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Bromocriptine.
VoriconazoleThe metabolism of Bromocriptine can be decreased when combined with Voriconazole.
VortioxetineVortioxetine may increase the hypoglycemic activities of Bromocriptine.
VortioxetineBromocriptine may increase the vasoconstricting activities of Vortioxetine.
XimelagatranThe serum concentration of Bromocriptine can be increased when it is combined with Ximelagatran.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Bromocriptine.
ZimelidineZimelidine may increase the hypoglycemic activities of Bromocriptine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Bromocriptine can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Bromocriptine.
ZolmitriptanBromocriptine may increase the vasoconstricting activities of Zolmitriptan.
ZotepineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  4. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
  5. Lahlou S: Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats. Fundam Clin Pharmacol. 1999;13(6):624-34. [PubMed:10626749 ]
  6. Lahlou S, Araujo Lima PF, Interaminense LF, Duarte GP: Blunted central bromocriptine-induced tachycardia in conscious, malnourished rats. Pharmacol Toxicol. 2003 Apr;92(4):189-94. [PubMed:12753422 ]
  7. Lahlou S, Lima GC, Leao-Filho CS, Duarte GP: Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats. Can J Physiol Pharmacol. 2000 Mar;78(3):260-5. [PubMed:10721819 ]
  8. Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L: Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine. 2001 Apr;14(3):329-36. [PubMed:11444429 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Knight JA, Smith C, Toohey N, Klein MT, Teitler M: Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Mol Pharmacol. 2009 Feb;75(2):374-80. doi: 10.1124/mol.108.052084. Epub 2008 Nov 7. [PubMed:18996971 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Fernando H, Halpert JR, Davydov DR: Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration. Biochemistry. 2006 Apr 4;45(13):4199-209. [PubMed:16566594 ]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132 ]
  3. Nath A, Grinkova YV, Sligar SG, Atkins WM: Ligand binding to cytochrome P450 3A4 in phospholipid bilayer nanodiscs: the effect of model membranes. J Biol Chem. 2007 Sep 28;282(39):28309-20. Epub 2007 Jun 15. [PubMed:17573349 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  2. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
  3. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  4. Renaud JP, Davydov DR, Heirwegh KP, Mansuy D, Hui Bon Hoa GH: Thermodynamic studies of substrate binding and spin transitions in human cytochrome P-450 3A4 expressed in yeast microsomes. Biochem J. 1996 Nov 1;319 ( Pt 3):675-81. [PubMed:8920966 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 02:35